Abbvie Inc
NYSE:ABBV
Abbvie Inc
Additional Paid In Capital
Abbvie Inc
Additional Paid In Capital Peer Comparison
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$20.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$6.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
2%
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Moderna Inc
NASDAQ:MRNA
|
Additional Paid In Capital
$371m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$7.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$11.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
See Also
What is Abbvie Inc's Additional Paid In Capital?
Additional Paid In Capital
20.2B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Additional Paid In Capital amounts to 20.2B USD.
What is Abbvie Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
19%
Over the last year, the Additional Paid In Capital growth was 5%. The average annual Additional Paid In Capital growth rates for Abbvie Inc have been 5% over the past three years , 6% over the past five years , and 19% over the past ten years .